1. Home
  2. POM vs PHIO Comparison

POM vs PHIO Comparison

Compare POM & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POMDOCTOR LIMITED American Depositary Shares

POM

POMDOCTOR LIMITED American Depositary Shares

HOLD

Current Price

$0.69

Market Cap

11.3M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.04

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
PHIO
Founded
2015
2003
Country
China
United States
Employees
165
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
11.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
POM
PHIO
Price
$0.69
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
55.2K
388.4K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.81
52 Week High
$6.43
$4.19

Technical Indicators

Market Signals
Indicator
POM
PHIO
Relative Strength Index (RSI) 40.50 49.93
Support Level $0.63 $1.00
Resistance Level $1.78 $1.14
Average True Range (ATR) 0.19 0.08
MACD -0.08 0.00
Stochastic Oscillator 15.98 65.00

Price Performance

Historical Comparison
POM
PHIO

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: